HB0025

Phase 2Small molecule

SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0025 is one of 45 small molecule programs targeting First Line Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First Line TherapyEnrolling by invitation

Advanced Solid TumorRecruiting

First Line TherapyPhase 2

Enrolling by invitation

Advanced Solid TumorPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Advanced Solid Tumor

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

4 2

Mekinist

Novartis

Phase 2

2 3

Fludara

Sanofi

Phase 2

1 4

Tafinlar

Novartis

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

3 6

Alimta

SShawn Eagle

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 10

Zytiga

Johnson & Johnson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT07383116

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Unknown status·HHuabo Biopharm Co., Ltd.·Phase 1·NCT04678908·154 enrolled

Non-Small Cell Lung Cancer1 trial

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Not yet recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 3·NCT07383116·500 enrolled

Advanced Solid Tumor1 trial

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Recruiting·HHuabo Biopharm Co., Ltd.·Phase 1/2·NCT06758557·282 enrolled

Advanced Renal Cancer1 trial

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Unknown status·HHuabo Biopharm Co., Ltd.·Phase 2·NCT06222125·100 enrolled

First Line Therapy1 trial

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Enrolling by invitation·HHuabo Biopharm Co., Ltd.·Phase 2·NCT07376629·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HB0025. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB0025 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB0025. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Huaota Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0025

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Solid Tumor1 trial

Advanced Renal Cancer1 trial

First Line Therapy1 trial

References

Drug Info

Quick Facts

Related News